The Zepbound and Mounjaro patents on tirzepatide
- Composition of Matter Patent (US 9,474,780): The patent that matters most here covers tirzepatide's exact molecular structure and its dual-agonist design. Structural tweaks are crucial (adding aminoisobutyric acid, plus a C20 fatty acid chain) and they are what let the drug bind to GIP and GLP-1 receptors both, and stay active for a week in the body. January 2036 is when this primary patent runs out. [1, 2]
- Formulation & Manufacturing Patents: Eli Lilly and Company also holds secondary patents covering the drug's stability, how it is delivered, and its injection solutions — and those can stretch protection out as far as June 2039. [1, 2]
- Regulatory Exclusivity: Tirzepatide carries a New Chemical Entity (NCE) designation, which brings a statutory window of FDA exclusivity: normally no rival maker can get an identical active ingredient approved before 2027. [1]